13 research outputs found
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced NonâSmall-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
AbstractBackgroundIn a phase III trial of patients with unresectable, locally advanced, stage III nonâsmall-cell lung cancer (NSCLC) with a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy alone, except among performance status (PS) 2 patients. In the present subgroup analysis, we evaluated the effect on patients aged ⼠70 years (42% of all included) compared with patients aged < 70 years enrolled in the trial.Patients and MethodsAll patients received 4 courses of intravenous carboplatin and oral vinorelbine. The experimental arm also received radiotherapy (42 Gy in 15 fractions). The included patients were required to have large tumors (> 8 cm), weight loss (> 10% within the previous 6 months) and/or PS 2.ResultsThe overall survival was increased among the CRT patients in both age groups, but the difference was significant only in patients aged < 70 years (median survival, 14.8 vs. 9.7 months; P = .001; age âĽÂ 70 years, median survival, 10.2 vs. 9.1 months; P = .09). Patients aged ⼠70 years experienced better preserved health-related quality of life (QOL) and significantly less hematologic toxicity. The 2- and 3-year survival was significantly increased in both age groups receiving CRT.ConclusionElderly patients aged ⼠70 years with unresectable, stage III, locally advanced, NSLCL and a poor prognosis can tolerate CRT with the doses adjusted to age and palliative intent. These results indicate that CRT can provide both survival and QOL benefits in elderly patients, except for those with PS 2 or worse. The male predominance in the ⼠70-year-age group and the reduced chemotherapy intensity for the patients aged > 75 years might explain the lack of significant survival improvement among those patients aged ⼠70 years
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell
lung cancer stage III and negative prognostic factors remains unresolved.
Methods: Patients not eligible for curative radiotherapy were randomised to receive either chemoradiation or chemotherapy
alone. Four courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 were given with 3-week intervals.
Patients in the chemoradiation arm also received radiotherapy with fractionation 42 Gy/15, starting at the second chemotherapy
course. The primary end point was overall survival; secondary end points were health-related quality of life (HRQOL) and toxicity.
Results: Enrolment was terminated due to slow accrual after 191 patients from 25 Norwegian hospitals were randomised. Median
age was 67 years and 21% had PS 2. In the chemotherapy versus the chemoradiation arm, the median overall survival was 9.7 and
12.6 months, respectively (Po0.01). One-year survival was 34.0% and 53.2% (Po0.01). Following a minor decline during treatment,
HRQOL remained unchanged in the chemoradiation arm. The patients in the chemotherapy arm reported gradual deterioration
during the subsequent months. In the chemoradiation arm, there were more hospital admissions related to side effects (Po0.05).
Conclusion: Chemoradiation was superior to chemotherapy alone with respect to survival and HRQoL at the expense of more
hospital admissions due to toxicity
Advanced Non-small Cell Lung Cancer Effects of Chemotherapy and Impact on Health Related Quality of Life
Avhandlingen presenterer behandlingseffekt, bivirkninger og livskvalitet hos lungekreftpasienter som fĂĽr moderne cellegiftbehandling. Pasientene med performance status (PS) 2 er etterpĂĽ vurdert separat.
Avhandlingens tittel er âAdvanced non-small cell Lung Cancer â Effects of Chemotherapy and Impact on Health Related Quality of Lifeâ. Den ble forsvart for graden PhD 13.03.2009. PĂĽ verdensbasis er lungekreft den vanligste kreftsykdommen og den som forĂĽrsaker flest kreftrelaterte dødsfall. I Norge dør rundt 2000 mennesker av lungekreft hvert ĂĽr. De fleste pasientene har langtkommet sykdom og kan ikke kureres. MĂĽlet med behandling er forlengelse av livet og best mulig livskvalitet. Avhandlingen tar utgangspunkt i VING-studien som ble gjennomført for ĂĽ undersøke om det var ulik overlevelse, bivirkningsprofil og livskvalitet forbundet med to ulike cellegiftkombinasjoner. Ca 40 % av pasientene med langtkommet lungekreft er i dĂĽrlig allmenntilstand ved diagnosetidspunktet. I avhandlingen vurderes nytte og effekt av behandlingen for pasienter med PS 2.
VING-studien var en nasjonal multisenter fase III studie utgütt fra Norsk Lungekreftgruppe. Fra september 2003 til desember 2004 inkluderte 33 sykehus over hele landet 432 pasienter i studien. Pasientene fikk tre cellegiftkurer med tre ukers mellomrom, enten vinorelbin/carboplatin, eller gemcitabin/carboplatin. De fylte ut livskvalitetsskjema ved studiens start, før hver kur og deretter regelmessig ved kontroller. Sammenligning av de to behandlingsalternativene viste at overlevelse og livskvalitet var den samme, men at behandling med vinorelbin gir mindre tiltakskrevende bivirkninger. Som en konsekvens av dette, ble cellegiftkombinasjonen vinorelbin/carboplatin standardbehandling ved langtkommet lungekreft i Norge. Undersøkelser av hvordan PS 2 pasientene tülte behandlingen, viste at disse hadde gevinst av behandlingen. De oppnüdde bedring i generell livskvalitet og pusteproblemer, samt mindre smerter, utmattelse, søvn- og appetittproblemer. Man frykter at cellegiftbehandling er en for stor pükjenning for de sykeste, men disse resultatene tyder pü at man i større grad enn tidligere bør tilby behandling til pasienter som ønsker det
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Introduction: Poor prognosis patients with bulky stage III locally
advanced nonâsmall-cell lung cancer may not be offered concurrent
chemoradiotherapy (CRT). Following a phase III trial concerning the
effect of palliative CRT in inoperable poor prognosis patients, this
analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL).
Methods: A total of 188 poor prognosis patients recruited in a randomized clinical trial received four courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8, at 3-week intervals. The
experimental arm (N = 94) received radiotherapy with fractionation
42 Gy/15, starting at the second chemotherapy course. This subset
study compares outcomes in patients with tumors larger than 7cm
(N = 108) versus tumors 7 cm or smaller (N = 76).
Results: Among those with tumors larger than 7cm, the median
overall survival in the chemotherapy versus CRT arm was 9.7 and
13.4 months, respectively (p = 0.001). The 1-year survival was 33%
and 56%, respectively (p = 0.01). Except for a temporary decline
during treatment, HRQOL was maintained in the CRT arm, regardless of tumor size. Among those who did not receive CRT, patients
with tumors larger than 7cm experienced a gradual decline in the
HRQOL. The CRT group had significantly more esophagitis and hospitalizations because of side effects regardless of tumor size.
Conclusion: In patients with poor prognosis and inoperable locally
advanced nonâsmall-cell lung cancer, large tumor size should not
be considered a negative predictive factor. Except for performance
status 2, patients with tumors larger than 7 cm apparently benefit
from CRT
Does chemotherapy improve Quality of Life in NSCLC PS 2?
Introduction
Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These patients have a shorter life expectancy than PS 0/1 patients and they are underrepresented in clinical trials. Data on how platinum-based combination chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are scarce and the treatment of this important group of patients is controversial.
Methods
A national multicenter phase III study on platinum based chemotherapy to 432 advanced NSCLC patients included 123 patients with PS 2. To explore the treatment impact on HRQOL, the development of HRQOL during the first nine weeks were compared between PS 2 and PS 0/1 patients. We used the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Standardized area under the curve for all HRQOL items, and HRQOL responses classified as better, stable or worse, were compared between the groups.
Results
Whereas the demographic data at baseline were well balanced between the groups, the PS 2 patients had significantly worse function and more severe symptoms than the PS 0/1 patients. In response to combination chemotherapy, the PS 2 patients had a more profound improvement of global QOL, cognitive function, fatigue, dyspnea, sleeping problems and appetite loss in comparison to the PS 0/1 group.
Conclusions
PS 2 NSCLC patients seem to achieve valuable HRQOL benefits from platinum-based combination therapy. Prospective clinical studies with predefined HRQOL outcomes in PS 2 patients are needed to confirm these findings
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gainâa model-based analysis
1
Norum J,
et al
.
ESMO Open
2017;
2
:e000222. doi:10.1136/esmoopen-2017-000222
Open Access
Abstr
A
ct
Background
P
embrolizumab is a new drug approved in
several countries for second-line therapy in non-small cell
lung cancer (NSCLC) being programmed cell death ligand
(PD-L1) positive. This drug has a high cost, and the cost-
effectiveness ratio has been debated.
Patients and methods
The budget impact to the Northern
Norwegian Regional Health
Authority trust of implementing
pembrolizumab in second-line therapy in patients with
PD-L1-positive NSCLC was calculated. A model was
developed employing data from the Cancer Registry of
Norway, the KEYNOTE-010 study, the price list from The
Hospital Pharmacy of North Norway, the cost of analysing
PD-L1 expression and the cost of travelling. Todayâs
cost of second-line therapy was compared with the new
standard employing pembrolizumab. The sale price of
pembrolizumab in Norway was not published due to price
confidentiality. Norwegian krone (NKr) was converted into
Euros (
âŹ
) at a rate of 1
âŹ
=Nkr 8.8138. (Bank of Norway,
21 February 2017).
Results
105 new pa
tients were identified available
for pembrolizumab per year. The annual cost of
pembrolizumab was
âŹ
5.2
million,
hospital pharmacy
administration costs
âŹ
0.1
million,
PD-L1 testing
âŹ
0.3
million, oncologist/pulmonologist/nurses
âŹ
0.2
million, radiology
âŹ
0.06
million and transporta
tion
âŹ
0.4
million.
Savings due to avoided present second-line
therapy was calculated
âŹ
0.4
million.
Consequently, the
cost of implementing pembrolizumab was
âŹ
5.5
million and
the annual budget impact was
âŹ
5.0
million.
A mean gain
of at least 9 months per patient treated was necessary to
make pembrolizumab cost-effective.
Conclusions
The net budget impact of pembrolizumab
was
âŹ
5.0
million.
The expenditure could not be indicated
cost-effective. Price confidentiality is a growing problem
in health economics and it has become a âmenu without
pricesâ setting
PD4-2-4: Outcome of patients with WHO performance status 2 in a randomized trial comparing vinorelbine/carboplatin with gemcitabine/carboplatin in advanced NSCLC
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Introduction
There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are studied.
Methods
National data on cancer incidence and vital status are virtually complete. Changes in incidence and survival are described by absolute numbers, percentages, and calculation of relative survival (period analysis).
Results
A total of 44,825 individuals were diagnosed with lung cancer in Norway in the study period. The number of incident cases increased with 49% whereas the prevalence increased with 136% from 2000 to 2016. Age-standardised rates rose markedly for women and levelled off for men. In 2016, adenocarcinoma accounted for about 50% of all lung cancers, slightly more for women than for men. The entity âNSCLC not otherwise specifiedâ declined from 24% to 13%, and the fraction of patients with metastatic disease decreased from 54% to 46% during the period, for both sexes combined.
The overall median survival time doubled for women and men, reaching 14.3 months and 11.4 months, respectively. For patients with metastatic disease, median survival time showed a small increase but remained less than 6 months. The overall 5-year relative survival increased from 16% to 26% in women and from 16% to 22% in men. The corresponding improvements for the subgroup of non-surgically treated cases with localised disease, were up from 25% to more than 40% in females, and from 10% to almost 40% in males.
Conclusion
There have been notable changes in incidence patterns and a remarkable improvement in survival for lung cancer over the last 17 years, most markedly for patients without distant metastases at the time of diagnosis. Hopefully, survival will improve even more when immunotherapy is implemented
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Introduction
There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are studied.
Methods
National data on cancer incidence and vital status are virtually complete. Changes in incidence and survival are described by absolute numbers, percentages, and calculation of relative survival (period analysis).
Results
A total of 44,825 individuals were diagnosed with lung cancer in Norway in the study period. The number of incident cases increased with 49% whereas the prevalence increased with 136% from 2000 to 2016. Age-standardised rates rose markedly for women and levelled off for men. In 2016, adenocarcinoma accounted for about 50% of all lung cancers, slightly more for women than for men. The entity âNSCLC not otherwise specifiedâ declined from 24% to 13%, and the fraction of patients with metastatic disease decreased from 54% to 46% during the period, for both sexes combined.
The overall median survival time doubled for women and men, reaching 14.3 months and 11.4 months, respectively. For patients with metastatic disease, median survival time showed a small increase but remained less than 6 months. The overall 5-year relative survival increased from 16% to 26% in women and from 16% to 22% in men. The corresponding improvements for the subgroup of non-surgically treated cases with localised disease, were up from 25% to more than 40% in females, and from 10% to almost 40% in males.
Conclusion
There have been notable changes in incidence patterns and a remarkable improvement in survival for lung cancer over the last 17 years, most markedly for patients without distant metastases at the time of diagnosis. Hopefully, survival will improve even more when immunotherapy is implemented
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responsesâthe ComIT-1 trial
The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (n = 21) with advanced non-small-cell lung cancer treated with atezolizumab and stereotactic body radiotherapy in the second or later line. We found the combined treatment to be safe with grade 3 toxicity reported in three patients. As the best overall response, four patients had a partial response, eight had stable disease and five had progressive disease. Median overall survival time was still not reached after a median follow-up of 26.5âmonths and 10/15 patients with programmed death-ligand 1 negative tumours were alive >18âmonths after the start of the study treatment. ctDNA was detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of baseline levels was seen in three patients, two of which were radiographic responders and one was considered clinically benefiting from therapy for almost 1âyear